Sector News

Valeant grabs a Middle Eastern foothold with $800M pact for Egypt’s Amoun

July 20, 2015
Life sciences
Last month, reports said Valeant was stepping up talks on a deal for one of Egypt’s largest drugmakers. And now, it’s pulled the trigger.
 
The serial buyer has agreed to shell out $800 million on Amoun Pharmaceutical–plus contingent payments, it said in a statement. With that, it’ll grab the leading position in Egypt’s domestic pharma market and gain access to brands in the antihypertensive, broad-spectrum antibiotic and antidiarrheal spaces. Amoun is expecting to hit $223.5 million in sales this year and record a top-line swell of about 20%.
 
But Valeant isn’t expecting to keep its new business confined to Egypt. Rather, the Canadian pharma intends for Amoun to “serve as a platform for further expansion” in the Middle East and North Africa, emerging markets that CEO J. Michael Pearson likes for their speedy growth.
 
Beefing up in developing nations has been on Pearson’s agenda for a while now; it was one perk of the proposed Allergan ($AGN) merger, which Actavis eventually spoiled with a white knight swoop-in late last year. Since then, Valeant has made a pair of other acquisitions, though those–a buyout of North Carolina’s Salix and a pickup of bankrupt Dendreon’s assets–focused on different fast-expanding fields (GI and oncology, respectively).
 
Another burgeoning area Valeant’s long had on its radar? Animal health. Last month, sources told The Wall Street Journal it had approached market leader Zoetis, a company in which former deal partner Bill Ackman’s Pershing Square Capital Management holds a stake.
 
By Carly Helfand
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach